Radiotherapy in Hepatocellular Carcinomas After Hepatectomy With Narrow Margin (<1 cm) and / or Microvascular Invasion
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
Hepatocellular carcinoma is one of ten leading cancer types worldwide and also in Asia, but
the five-year relative survival rate is relatively quite low1-3. For hepatocellular carcinoma
treatment, current options are surgical resection, embolization chemotherapy, radiation
therapy, a variety of ablation therapy, biological and gene therapy, etc. Among them, the use
of radiation therapy is getting more and more attention, and it is changing from the past
palliative treatment to current curable treatment. From an oncologic point of view, a narrow
margin <1 cm and microvascular invasion is not safe and is often associated with higher rates
of recurrence and shorter patient survival.On the other hand, it is also believed that most
intrahepatic recurrences arise from multicentric carcinogenesis and are distant from the
resection margin. To address this issue, the investigators are going to conduct a series of
retrospective and prospective studies to investigate the effect of adjuvant Radiotherapy for
centrally located hepatocellular carcinoma after narrow margin (<1 cm) hepatectomy on tumor
recurrence.